Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Ryan D. Chow (15109654) (author)
Rannpháirtithe:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
de réir: Ryan D. Chow (15109654)
Foilsithe / Cruthaithe: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
de réir: Ryan D. Chow (15109654)
Foilsithe / Cruthaithe: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
de réir: Ryan D. Chow (15109654)
Foilsithe / Cruthaithe: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
de réir: Zannel Blanchard (16617018)
Foilsithe / Cruthaithe: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
de réir: Zannel Blanchard (16617018)
Foilsithe / Cruthaithe: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
de réir: Zannel Blanchard (16617018)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
de réir: Niccolò G. Santin (22229756)
Foilsithe / Cruthaithe: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
de réir: Yumeng Cai (5591276)
Foilsithe / Cruthaithe: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
de réir: Cheng Wang (102692)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
de réir: Shigehiro Yagishita (15088446)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
de réir: Shigehiro Yagishita (15088446)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
de réir: Shigehiro Yagishita (15088446)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
de réir: Shigehiro Yagishita (15088446)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
de réir: Arnaud Da Cruz Paula (17316230)
Foilsithe / Cruthaithe: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
de réir: Yi Tang (55726)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)